Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test
PR Newswire•29/10/2026•09:00 ET
0
Key Highlights
- ➤12 of 20 HPV-positive women had high-grade lesions or invasive cervical cancer
- ➤625 women screened using CoSara’s SARAGENE HPV-HR test in Central Gujarat
- ➤18 of 20 HPV-positive women had negative cytology results
- ➤CoSara expanded planned distribution territory to Bangladesh, Pakistan, Nepal and Sri Lanka
- ➤Co-Dx developing separate HPV test for Co-Dx PCR Pro platform
Expert Statements
Dwight Egan, Chief Executive Officer of Co-Diagnostics
“Expanding access to molecular HPV testing is an important part of strengthening cervical cancer screening, particularly in regions where access to diagnostics remains limited.”
Dwight Egan, Chief Executive Officer of Co-Diagnostics
“We are excited to see CoSara's SARAGENE® test used in published research that brings the importance of molecular screening into such clear focus.”
Dwight Egan, Chief Executive Officer of Co-Diagnostics
“Our goal through CoSara is to make high-quality, affordable molecular diagnostics more accessible to laboratories and clinicians across India and South Asia.”
Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test PR Newswire
Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology Results
Get started
Create a free account to read the full story.